Moderna shares rose sharply Monday following news that the company is applying to regulators in the US and Europe for permission for the supply and sale of its vaccine against the coronavirus, which has shown efficacy in 94.1%, without serious side effects.
Stock Moderna (MRNA), an increase of 550% since the beginning of the year, rose more than 20% Monday after the company confirmed the high efficiency of its vaccine COVID-19 and stated the intention to apply for permission to use his vaccine in an emergency situation in the U.S. and Europe.
It is expected that the test vaccine Moderna by Management on sanitary inspection behind quality of foodstuff and medicines (FDA) will take a few weeks. The Agency will likely schedule a meeting of the Advisory Committee for consideration of the vaccine on 17 December, said the representative of Moderna.
The company Moderna will be the second after Pfizer (PFE) and BioNTech, who had requested permission for the emergency use from the FDA for its vaccine COVID-19 20 Nov.
The news for these pharmaceutical companies has a beneficial impact on the US stock market, as investors consider the vaccine as a way to get the global economy back to normal. The global number of deaths from COVID-19 exceeded 1.46 million, according to the Johns Hopkins University.
Moderna reported that according to the study, vaccine efficacy at 94.1% was the same for all ages, races and gender. None of the volunteers who received two doses of vaccine do not get sick COVID-19. The vaccine was declared safe because serious side effects have been identified among short-term reactions to the vaccine were fatigue, muscle pain, headache and pain at the injection site.
Moderna said Monday that it plans to test the vaccine on children aged 11 to 17 years at the end of this year.
Previously, Moderna announced that they are ready to deliver about 20 million doses in the United States, and the current plan deliveries worldwide by 2021 ranges from 500 million to 1 billion doses.
In August, Moderna announced that the provisional price of one dose of its vaccine would range from $32 to $37 and below for large orders.
The company began a consistent flow of applications in several regulatory agencies worldwide, including the European medicines Agency.
The advantage of the vaccine Moderna compared to the Pfizer vaccine is that it does not require storage at ultra low temperature. While the vaccine “BNT162b1” Pfizer requires conditions in -34.4 °C, which complicates storage and transportation for vaccines Moderna valid range is from -7,7 °C to -2.2 °C, which simplifies its distribution.
Representatives of the medical and public health experts note that it remains unclear how long the vaccine will provide immunity and whether people need periodic booster vaccinations and how often.
